Erschienen in:
01.12.2001 | Paper Report
Dual HER-2/EGFR tyrosine kinase inhibitors
verfasst von:
Fatima Cardoso
Erschienen in:
Breast Cancer Research
|
Ausgabe 1/2000
Einloggen, um Zugang zu erhalten
Excerpt
Cancer therapy has been changing from conventional nonspecific treatments to selective targeted therapies.
EGFR and
HER-2 are co-expressed in a variety of tumour types. The available tyrosine kinase inhibitors are moving to phase II and phase III clinical trials, with a favourable toxicity profile. There is a biological rational for attempting to block the growth factors signalling pathways at several sites simultaneously. The use of a dual inhibitor of both EGFR and HER-2 could provide a therapeutic benefit to a broad patient population. …